HTG EdgeSeq PATH Assay

HTG Molecular Diagnostics plans to launch the HTG EdgeSeq PATH Assay for research use only by the end of the second quarter. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry (IHC) testing. The test assesses mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded sample availability is limited, the company said. It is designed to detect up to 470 mRNA targets, typically assessed by IHC.